Sophiris Bio is a biopharmaceutical company focused on products for the treatment of urological diseases. Co. is developing topsalysin (PRX302) as a treatment for clinically significant localized prostate cancer and as a treatment for the lower urinary tract symptoms of benign prostatic hyperplasia, commonly referred to as an enlarged prostate. Topsalysin, a genetically modified recombinant protein, is delivered via ultrasound-guided injection directly into the prostate. This protein is selectively activated by enzymatically active prostate specific antigen, which is in the prostate, resulting in localized cell death and tissue disruption without damage to neighboring tissue and nerves.
Zacks Investment Research is a Chicago based firm with over 30 years of experience in providing institutional and individual investors with the analytical tools and financial information necessary to the success of their investment process.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.